STAT

SEPTEMBER 23, 2022

Market share is often held up as the most relevant metric for the success of a biosimilar class. I believe there are other metrics, like cost savings or signs of greater patient access, that should also be used to define biosimilars’ successes or failures. the first biosimilar was launched in September 2015. In the U.S.,

Biosimilars 245

Biosimilars Diabetes Drug Pricing 245

pharmaphorum

APRIL 13, 2022

The treatment has been around for over a century but insulin has still become the centre of the ongoing discussion over pricing of pharmaceutical products. Ben Hargreaves looks at why insulin’s price is so controversial and whether this could be set to change. In the US, approximately 37.3 In the US, approximately 37.3

Drug Pricing 130

Drug Pricing Diabetes Biosimilars 130

STAT

MARCH 15, 2024

Thanks to the rising use of various blockbuster drugs, but particularly the so-called GLP-1 medications for treating obesity and diabetes, the outlook for earnings for the pharmaceutical industry is positive over the next 12 to 18 months , according to Moody’s Investor Services. Continue to STAT+ to read the full story…

Drug Pricing 236

Drug Pricing Biosimilars Diabetes 236

pharmaphorum

JANUARY 28, 2021

It has been five years since the first biosimilar launched in United States market—marking the first steps in expanding access to innovative biologic-based treatments that help patients manage and treat difficult illnesses such as cancer, rheumatoid arthritis, and other life-altering diseases. million patients.

Biosimilars 119

Biosimilars Insurance Coverage and Processing Drug Pricing Diabetes 119

pharmaphorum

JANUARY 13, 2023

.” He added that people from low-income households and some racial and ethnic groups are disproportionately impacted by the practices, including Hispanic and Black people, who are much more likely to be diagnosed with diabetes than non-Hispanic white people – and much more likely to die as a result of complications.

Diabetes 105

Diabetes Drug Pricing Biosimilars 105

Express Pharma

SEPTEMBER 6, 2023

According to the World Health Organisation (WHO), an estimated two billion people across the world do not have access to essential medicines for life threatening diseases like cancer, AIDS and even autoimmune diseases like Type 1 diabetes. The post Is India capable of ensuring equitable access to biopharmaceuticals?

Insurance Coverage and Processing 59

Insurance Coverage and Processing Biosimilars Generic Medicine Drug Pricing 59

Pharmaceutical Technology

DECEMBER 20, 2022

The growing competition from generic drugs presents challenges for the top 20 players placing pressure on drug prices. Although AbbVie’s Humira (adalimumab) is set to face biosimilar competition next year, the blockbuster drug reported strong US sales of $4.96

Vaccines 52

Vaccines Diabetes Drug Pricing Biosimilars 52